Diabetes mellitus is a metabolic disorder resulting from a gradual decline in pancreatic beta cell function (type 2 diabetes mellitus, T2DM) or from autoimmune destruction of pancreatic beta cells (type 1 diabetes mellitus, T1DM). Decreasing function in these specialized cells impacts both insulin secretion and sensitivity, resulting in variable blood glucose levels and a complex metabolic response that affects many organs. Diabetes continues to be one of the most common chronic conditions as its prevalence rises from year to year.
Uncontrolled blood glucose is extraordinarily damaging for all diabetics. Patients on insulin therapy have traditionally relied on finger stick tests for routine self-monitoring of blood glucose (SMBG). However, many patients find relying on finger stick methods painful, leading to a significant compliance issues. This activity will provide pharmacists with a foundational understanding of the clinical consequences associated with variable blood glucose levels in order to advocate and educate patients about monitoring devices.
The target audience for this activity includes pharmacists. At the completion of this activity, the participant will be able to:
- Discuss epidemiology, risk factors, and clinical impact of diabetes mellitus (DM) in the US.
- Compare and contrast FDA-approved devices for continuous glucose monitoring (CGM) by device type, data analytics, and connectivity.
- Describe individualized strategies to educate patients on CGM across health-systems, ambulatory care clinics, and community and specialty pharmacies.
Susan Cornell, BS, PharmD, CDCES, FAPhA, FADCES
Associate Director of Experiential Education
Associate Professor of Pharmacy Practice
Midwestern University Chicago College of Pharmacy
Downers Grove, Illinois
Bruce L. Lambert, PhD
Director, Center for Communication and Health
Professor, Department of Communication Studies and Medical Social Sciences
Release Date: December 15, 2020
Expiration Date: December 31, 2021
ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-20-529-H01-P has been assigned to this home study knowledge-based activity. This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. Cornell is a speaker and advisory board member for Novo Nordisk. Dr. Lambert is a consultant for Abbott, Boehringer Ingelheim, and RLDatix.
This activity is supported by an educational grant from Abbott Diabetes Care.
The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.